CU23317A1 - Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central - Google Patents

Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central

Info

Publication number
CU23317A1
CU23317A1 CU20050138A CU20050138A CU23317A1 CU 23317 A1 CU23317 A1 CU 23317A1 CU 20050138 A CU20050138 A CU 20050138A CU 20050138 A CU20050138 A CU 20050138A CU 23317 A1 CU23317 A1 CU 23317A1
Authority
CU
Cuba
Prior art keywords
eporh
nasal
basic
treatment
sialic acid
Prior art date
Application number
CU20050138A
Other languages
English (en)
Inventor
Bal Armestrong Joaqua N Solaza
Alejo Vivian Montero
Martinez Nelvys Subiros
Rodra Guez Janette Cruz
Rodra Guez David Curbelo
Testa Iliana Sosa
Ruiz Zenia Pardo
A Rodra Guez Julio Ca Sa Garca
Oz Cernuda Adriana Muaa
Ez Figueredo Yanier Nuaa
A Salman Jorge Daniel Garca
Original Assignee
Ct De Investigacia N Y Desarro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Investigacia N Y Desarro filed Critical Ct De Investigacia N Y Desarro
Priority to CU20050138A priority Critical patent/CU23317A1/es
Priority to EP06761631.8A priority patent/EP1997483B1/en
Priority to CA2616156A priority patent/CA2616156C/en
Priority to CNA200680034781XA priority patent/CN101296692A/zh
Priority to BRPI0615541-3A priority patent/BRPI0615541A2/pt
Priority to TR2018/15428T priority patent/TR201815428T4/tr
Priority to PCT/CU2006/000007 priority patent/WO2007009404A1/es
Priority to CN201510674598.7A priority patent/CN105435212A/zh
Priority to AU2006272217A priority patent/AU2006272217A1/en
Priority to MX2008000997A priority patent/MX2008000997A/es
Publication of CU23317A1 publication Critical patent/CU23317A1/es
Priority to HK16104978.0A priority patent/HK1216993A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con la Industria Biofarmacéutica y en particular con el desarrollo de un medicamento para el tratamiento de las enfermedades cerebrovasculares, neurodegenerativas y psiquiátricas que contiene como principio activo Eritropoyetina humana recombinante (EPOrh) con bajo contenido de ácido siálico. Durante la producción de EPOrh se obtiene esta glicoproteína con diferente contenido de ácido siálico cuando presenta menos de un 40 % de su molécula protegida con ácido siálico (básica), no es biológicamente activa por vía sistémica, es inactivada por enzimas hepáticas. Sorprendentemente hemos encontrado que la EPOrh básica administrada por vía nasal tiene utilidades terapéuticas superiores a la ácida. Las formulaciones nasales de EPOrh básica que se presentan incorporan polímeros bioadhesivos que incrementa el tiempo de residencia en la cavidad nasal potenciando su efecto terapéutico, se incluyen además otras sustacias auxiliares tales como, sustancias preservantes, tenso activos, reguladores de pH, agentes isotonizantes y estabilizadores de proteína.</P>
CU20050138A 2005-07-22 2005-07-22 Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central CU23317A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU20050138A CU23317A1 (es) 2005-07-22 2005-07-22 Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
TR2018/15428T TR201815428T4 (tr) 2005-07-22 2006-07-27 Merkezi sinir sistemi hastalıklarının tedavisi için düşük siyalik asit konsantrasyonuna sahip rh-EPO nasal formülasyonları.
CA2616156A CA2616156C (en) 2005-07-22 2006-07-27 Nasel formulations of recombinant human erythropoietin (rhepo) with low content of sialic acid for the treatment of diseases of the central nervous system
CNA200680034781XA CN101296692A (zh) 2005-07-22 2006-07-27 用于治疗中枢神经系统疾病的含有低浓度唾液酸的重组人红细胞生成素的鼻用制剂
BRPI0615541-3A BRPI0615541A2 (pt) 2005-07-22 2006-07-27 formulaÇÕes nasais de eritropoietina recombinante humana (rhuepo) com baixo conteédo de Ácido siÁlico para o tratamento de doenÇas do sistema nervoso central
EP06761631.8A EP1997483B1 (en) 2005-07-22 2006-07-27 Rh-epo nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system
PCT/CU2006/000007 WO2007009404A1 (es) 2005-07-22 2006-07-27 Formulaciones nasales de eporh con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central.
CN201510674598.7A CN105435212A (zh) 2005-07-22 2006-07-27 用于治疗中枢神经系统疾病的含有低浓度唾液酸的重组人红细胞生成素的鼻用制剂
AU2006272217A AU2006272217A1 (en) 2005-07-22 2006-07-27 Rh-epo nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system
MX2008000997A MX2008000997A (es) 2005-07-22 2006-07-27 Formulaciones nasales de eporh con bajo contenido de acido sialico para el tratamiento de enfermedades del sistema nervioso central.
HK16104978.0A HK1216993A1 (zh) 2005-07-22 2016-04-29 用於治療中樞神經系統疾病的含有低濃度唾液酸的重組人紅細胞生成素的鼻用製劑

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050138A CU23317A1 (es) 2005-07-22 2005-07-22 Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central

Publications (1)

Publication Number Publication Date
CU23317A1 true CU23317A1 (es) 2008-10-22

Family

ID=40122422

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050138A CU23317A1 (es) 2005-07-22 2005-07-22 Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central

Country Status (10)

Country Link
EP (1) EP1997483B1 (es)
CN (2) CN101296692A (es)
AU (1) AU2006272217A1 (es)
BR (1) BRPI0615541A2 (es)
CA (1) CA2616156C (es)
CU (1) CU23317A1 (es)
HK (1) HK1216993A1 (es)
MX (1) MX2008000997A (es)
TR (1) TR201815428T4 (es)
WO (1) WO2007009404A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937258B2 (en) 2013-07-17 2018-04-10 Dow Global Technologies Llc Composition for application to a nasal mucosa comprising a methylcellulose
CN104730070A (zh) * 2015-03-19 2015-06-24 邢海霞 一种联合检测唾液酸和羟脯氨酸的试剂及其检测方法
AU2017282933B2 (en) * 2016-06-20 2024-03-21 Centro De Inmunologia Molecular Use of the basic form of recombinant human erythropoietin in the treatment of patients with spinocerebellar ataxia with CAG repeat mutations
CU24704B1 (es) 2019-09-05 2024-04-08 Ct Inmunologia Molecular Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57146710A (en) 1981-03-07 1982-09-10 Kunio Yagi Blood brain-barrier permeating ribosome-like microcapsule
IT1212896B (it) 1983-11-08 1989-11-30 Della Valle Francesco Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
JPH01149718A (ja) 1987-12-07 1989-06-12 Yoshikatsu Eto 脳血液関門を通過し易いリポゾーム製剤
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
JP3850468B2 (ja) 1994-12-28 2006-11-29 中外製薬株式会社 エリスロポエチンのリポソーム製剤
IL140669A0 (en) * 1998-07-08 2002-02-10 Kirin Amgen Inc Powdery preparation for mucosal administration containing polymeric medicine
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
JP2007500243A (ja) * 2003-06-09 2007-01-11 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 成長ホルモンの増進された経粘膜送達のための組成物および方法

Also Published As

Publication number Publication date
AU2006272217A1 (en) 2007-01-25
EP1997483A1 (en) 2008-12-03
HK1216993A1 (zh) 2016-12-16
EP1997483A4 (en) 2014-05-21
CN105435212A (zh) 2016-03-30
TR201815428T4 (tr) 2018-11-21
CA2616156C (en) 2016-07-19
EP1997483B1 (en) 2018-07-18
MX2008000997A (es) 2008-03-14
WO2007009404A1 (es) 2007-01-25
BRPI0615541A2 (pt) 2013-02-13
CA2616156A1 (en) 2007-01-25
CN101296692A (zh) 2008-10-29

Similar Documents

Publication Publication Date Title
BRPI0507026A (pt) proteìnas de fusão de albumina
JP2023011696A (ja) 核酸産物およびその投与方法
TNSN08064A1 (en) Albumin fusion proteins
TR201906106T4 (tr) Amiyotrofik lateral skleroz ve diğer omurilik hastalıkları için gen tedavisi.
BR112022002599A2 (pt) Vesícula extracelular ligada a moléculas e usos da mesma
MX2023001461A (es) Composiciones para la administracion de moleculas de carga activa al epitelio de las vias respiratorias.
EA202191313A1 (ru) Композиции на основе липидных наночастиц
MX2011013258A (es) Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central.
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
EA031209B9 (ru) Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
BR0211807A (pt) Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos
CU23317A1 (es) Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
BRPI0710945A2 (pt) Propriedades fusogênicas de saposina c e proteínas e peptídeos relacionados para aplicação a sistemas de distribuição de fármaco transmembrana
MA38289A1 (fr) Composition pharmaceutique à biodisponibilité ameliorée
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
Jiang et al. Specially-made lipid-based assemblies for improving transmembrane gene delivery: comparison of basic amino acid residue rich periphery
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
BR112015003947A2 (pt) proteínas de fusão e métodos para tratar, prevenir ou melhorar dor
PE20110394A1 (es) Virus sincitial respiratorio vivo atenuado
ECSP10010516A (es) Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares
MY157947A (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity